Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer by Oue, Naohide et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Increased expression of h-prune is associated with tumorprogression and poor survival in gastric cancer
Auther(s) Oue, Naohide; Yoshida, Kazuhiro; Noguchi, Tsuyoshi;Sentani, Kazuhiro; Kikuchi, Akira; Yasui, Wataru
Citation Cancer Science , 98 (8) : 1198 - 1205
Issue Date 2007-08
DOI 10.1111/j.1349-7006.2007.00515.x
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00020725
Right Copyright (c) 2007 Blackwell Publishing. The definitiveversion is available at www.blackwell-synergy.com
Relation
Cancer Science  
Increased expression of h-prune is associated with tumor progression 
and poor survival in gastric cancer 
 
 
 
Naohide Oue 1, Kazuhiro Yoshida 2, Tsuyoshi Noguchi 3, Kazuhiro Sentani 1, Akira 
Kikuchi 4 and Wataru Yasui 1 
 
 
1Department of Molecular Pathology, Hiroshima University Graduate School of 
Biomedical Sciences, Hiroshima 734-8551; 2Department of Surgical Oncology, 
Research Institute for Radiation Biology and Medicine, Hiroshima University, 
Hiroshima 734-8551; 3Department of Oncological Science (Surgery II), Oita University 
Faculty of Medicine, Oita 879-5593; 4Department of Biochemistry, Hiroshima 
University Graduate School of Biomedical Sciences, Hiroshima 734-8551, Japan 
 
 
 
 
 
To whom correspondence should be addressed. E-mail: wyasui@hiroshima-u.ac.jp
 
1 
Cancer Science  
Abstract 
 
The human homolog of the Drosophila prune protein (from PRUNE, which encodes 
h-prune), which interacts with glycogen synthase kinase 3, promotes cellular motility. 
H-prune also interacts with nm23-H1, a suppressor of cancer metastasis. It has been 
reported that stimulation of cellular motility by h-prune is enhanced by its interaction 
with nm23-H1 in breast cancer cells. In the present study, we examined the expression 
of h-prune and nm23-H1 during tumor progression in gastric cancer (GC). PRUNE 
mRNA was overexpressed in 12 (32%) of 38 GC cases by quantitative reverse 
transcription–polymerase chain reaction. PRUNE mRNA levels correlated significantly 
with advanced T grade, N grade and tumor stage. Immunohistochemical analysis 
revealed that 43 (30%) of 143 GC cases were positive for h-prune, and h-prune-positive 
GC cases showed more advanced T grade, N grade and tumor stage than 
h-prune-negative GC cases. One hundred and twenty-four (87%) of 143 GC cases were 
positive for nm23-H1, and nm23-H1 was expressed in almost all (42 cases, 98%) 
h-prune-positive GC cases. Many GC cases positive for both h-prune and nm23-H1 
showed more advanced T grade, N grade and tumor stage than other type GC cases. 
Patients with h-prune-positive GC had a significantly worse survival rate than patients 
with h-prune-negative GC. These findings indicate that overexpression of h-prune is 
associated with tumor progression and aggressiveness of GC. nm23-H1 may enhance 
motility of cancer cells by interacting with h-prune. (Cancer Sci 2007; 98: 1198–1205) 
According to the World Health Organization, gastric cancer (GC) is the fourth most 
common malignancy worldwide, with approximately 870 000 new cases occurring 
yearly. Mortality due to GC is second only to that due to lung cancer.( 1) Advances in 
diagnostic tools and treatment have led to excellent long-term survival for early GC.( 2) 
However, despite improvements in diagnostic and therapeutic strategies, the prognosis 
of advanced GC with extensive invasion and metastasis remains poor. Several discrete 
steps can be discerned in the biological cascade of metastasis: loss of cellular adhesion, 
increased motility and invasiveness, entry and survival in the circulation, exit into new 
tissue, and eventual colonization of a distant site.( 3) Several molecules associated with 
invasion and metastasis have been identified,( 4,5) but these molecules cannot completely 
explain the mechanism of each step of metastasis. In addition, many genes have been 
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analyzed to understand the molecular basis of GC,( 6,7) but only a few with frequent 
alterations have been identified so far. 
Previously, we identified the human homolog of Drosophila prune protein (PRUNE, 
which encodes h-prune) as a glycogen synthase kinase 3 (GSK-3)-binding protein.( 8) 
GSK-3 inhibitors or small interfering RNA (siRNA) for GSK-3 and h-prune inhibit cell 
motility. H-prune is localized to focal adhesions, and the siRNA for GSK-3 or h-prune 
delays the disassembly of paxillin. Tyrosine phosphorylation of focal adhesion kinase 
(FAK) and activation of Rac are suppressed in GSK-3 or h-prune knock-down cells.( 8) 
These results suggest that GSK-3 and h-prune act cooperatively to regulate cellular 
motility. In fact, overexpression of h-prune has been reported in breast cancers and is 
also associated with high metastatic potential.( 9) In our previous study, overexpression 
of h-prune was correlated with T grade (depth of invasion), N grade (degree of lymph 
node metastasis), and tumor stage in colorectal cancers (CRC).( 8) 
H-prune has phosphodiesterase (PDE) activity, with a preferential affinity for cAMP 
over cGMP as substrate.( 9) PDE are a diverse superfamily of molecules that catalyze the 
hydrolysis of 3',5'-cyclic nucleotides to their corresponding nucleoside 
5'-monophosphates.( 10) H-prune PDE activity is involved in cellular motility,( 9) and 
h-prune also interacts with nm23-H1 (NME1, which encodes nm23-H1),( 11) a known 
suppressor of cancer metastasis.( 12) H-prune and nm23-H1 proteins partially colocalize 
in the cytoplasm.( 11) It has been suggested that overexpression of h-prune inhibits the 
antimetastasis function of nm23-H1 during the metastatic process.( 9,13) Several studies 
have suggested an association between reduced expression of nm23 mRNA or protein 
and increasing metastatic activity, resulting in poorer prognosis in breast cancers,( 14) 
malignant melanomas( 15) and hepatocellular carcinomas.( 16) In contrast, in GC and CRC, 
overexpression of nm23-H1 has been reported.( 17,18) High nm23-H1 expression has been 
shown to correlate with tumor progression and poor prognosis of GC.( 19) 
Taken together, the currently available data suggest that analysis of h-prune is necessary 
to clarify the association between expression of nm23-H1 and metastatic potential. 
Correlation between high nm23-H1 expression and metastatic potential in GC may be 
due to overexpression of h-prune. However, expression of h-prune has not been 
investigated in GC. In the present study, we examined the expression and distribution of 
both h-prune and nm23-H1 in human GC by immunohistochemistry and reverse 
transcription–polymerase chain reaction (RT-PCR). 
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Materials and Methods 
  
Tissue samples. In a retrospective study design, 181 primary tumors were collected 
from patients diagnosed with GC who underwent surgery between 1991 and 2001 at the 
Department of Surgical Oncology, Hiroshima University Hospital (Hiroshima, Japan). 
All patients underwent curative resection. Only patients without preoperative 
radiotherapy or chemotherapy and without clinical evidence for distant metastasis were 
enrolled in the study. 
For quantitative RT-PCR, 38 GC samples and corresponding non-neoplastic mucosa 
samples were used. The samples were obtained during surgery at Hiroshima University 
Hospital. We confirmed microscopically that the tumor specimens were predominantly 
cancer tissue (>50% on a nuclear basis). Samples were frozen immediately in liquid 
nitrogen and stored at –80°C until use. 
For immunohistochemical analysis, we used archival formalin-fixed, paraffin-embedded 
tissues from 143 patients who had undergone surgical excision for GC. Fifty-nine of the 
143 patients had early GC, and 84 had advanced GC. Early GC is limited to the mucosa 
or the mucosa and submucosa, regardless of nodal status.( 2) Advanced GC is a tumor 
that has invaded beyond the muscularis propria. Information on patient prognosis was 
available for 84 GC cases. Because information on postoperative chemotherapy was not 
available, postoperative chemotherapeutic backgrounds were not involved in the 
prognostic analysis. 
Tumor staging was carried out according to the tumor–node–metastasis (TNM) stage 
grouping.( 20) Histological classification of GC was carried out according to the Lauren 
classification system.( 21) Because written informed consent was not obtained, for strict 
privacy protection, identifying information for all samples was removed before analysis; 
this procedure is in accordance with Ethical Guidelines for Human Genome/Gene 
Research enacted by the Japanese Government and approved by the Ethical Review 
Committee of the Hiroshima University School of Medicine. 
Quantitative RT-PCR analysis. Total RNA was extracted with an RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA), and 1 µg of total RNA was converted to cDNA with a 
First Strand cDNA Synthesis Kit (Amersham Biosciences, Piscataway, NJ, USA). 
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Quantitation of PRUNE mRNA levels in human tissue samples was done by real-time 
fluorescence detection as described previously.( 22) PRUNE primer sequences were 
5'-GAA GTC CTG GAA CGC TCC C-3' and 5'-GGT TAG GGT GGG TAC TTG 
AGG C-3'. PCR was carried out using a SYBR Green PCR Core Reagents Kit (Applied 
Biosystems, Foster City, CA, USA). Real-time detection of the emission intensity of 
SYBR green bound to double-stranded DNA was done with an ABI PRISM 7700 
Sequence Detection System (Applied Biosystems) as described previously.( 23) 
ACTB-specific PCR products were amplified from the same RNA samples and served 
as internal controls. 
Immunohistochemistry. A Dako LSAB kit (Dako, Carpenteria, CA, USA) was used 
for immunohistochemical analysis. In brief, sections were pretreated by microwaving in 
citrate buffer for 30 min to retrieve antigenicity. After peroxidase activity was blocked 
with 3% H2O2–methanol for 10 min, sections were incubated with normal goat serum 
(Dako) for 20 min to block non-specific antibody binding sites. Sections were incubated 
with rabbit polyclonal antih-prune (diluted 1:50, antih-prune antibody was raised in our 
laboratory)( 8) and rabbit polyclonal antinm23-H1 (1:20, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA). The specificity of the h-prune antibody has been characterized 
in detail.( 8) Sections were incubated with primary antibody for 1 h at 25°C, followed by 
incubations with biotinylated antirabbit IgG and peroxidase-labeled streptavidin for 
10 min each. Staining was completed with a 10-min incubation with the 
substrate–chromogen solution. The sections were counterstained with 0.1% 
hematoxylin. The percentage of stained cancer cells was evaluated for each antibody. 
Statistical methods. Correlations between clinicopathological parameters and h-prune 
or nm23-H1 expression were analyzed by Fisher's exact test. Kaplan–Meier survival 
curves were constructed for h-prune- or nm23-H1-positive and h-prune- or 
nm23-H1-negative patients. Survival rates were compared between h-prune- or 
nm23-H1-positive and h-prune- or nm23-H1-negative groups. Differences between 
survival curves were tested for statistical significance using the log-rank test.( 24) Cox 
proportional hazards multivariate model was used to examine the association of clinical 
and pathological factors and the expression of h-prune with survival. A P-value of less 
than 0.05 was considered statistically significant. 
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Results 
  
mRNA expression of PRUNE in GC. Expression of PRUNE mRNA was analyzed 
by quantitative RT-PCR of RNA from 38 GC samples and corresponding 
non-neoplastic mucosa samples. We calculated the ratio of PRUNE mRNA levels 
between GC tissue (T) and corresponding non-neoplastic mucosa (N). When a T/N 
ratio > two-fold was considered to represent overexpression, PRUNE was 
overexpressed in 12 (32%) of the 38 GC samples. As shown in Fig. 1, PRUNE levels 
were significantly higher in T3/4 cases than in T1/2 cases (P = 0.0156; Mann–Whitney 
U-test). Moreover, PRUNE levels correlated significantly with N status (P = 0.0122; 
Mann–Whitney U-test) and tumor stage (P = 0.0127; Mann–Whitney U-test). There was 
no clear tendency between PRUNE level and histological type. 
Immunohistochemical analysis of h-prune in GC . We next investigated the 
expression and distribution of h-prune by immunohistochemistry of 143 GC tissue 
samples. In corresponding non-neoplastic gastric mucosa, only weak or no staining of 
h-prune was observed in epithelial and stromal cells (Fig. 2a,b). However, GC tissue 
showed stronger, more extensive staining than corresponding non-neoplastic mucosa. In 
14 (10%) of the 143 GC cases, h-prune-positive tumor cells were restricted to the 
invasive front (Fig. 2a,c,d). In these cases, less than 50% of tumor cells were stained. 
However, in the majority of GC cases containing h-prune-positive tumor cells, more 
than 50% of the tumor cells showed cytoplasmic staining for h-prune (43 of 143 GC 
cases). In these GC cases, h-prune-positive tumor cells were observed at the invasive 
front in addition to the central part of the tumors. The remaining cases showed 10–50% 
immunopositive tumor cells and h-prune staining was not observed at the invasive front. 
H-prune was detected in the cytoplasm of tumor cells in intestinal-type (Fig. 2e) and 
diffuse-type GC (Fig. 2f,g). We next analyzed the relationship between h-prune 
expression and clinicopathological characteristics. Several previous studies have 
indicated that observation of the invasive front is important in the analysis of tumor 
cells, because it reflects the invasive potential of those cells. To investigate the 
significance of restricted h-prune staining at the invasive front, the relationship between 
h-prune staining and clinicopathological characteristics was examined in GC cases in 
which less than 50% of tumor cells were stained. In these cases, GC cases in which 
h-prune-positive tumor cells were restricted to the invasive front showed more advanced 
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T grade (P = 0.0083, Fisher's exact test) than those in which h-prune-positive tumor 
cells were not restricted to the invasive front (Table 1). GC cases in which 
h-prune-positive tumor cells were restricted to the invasive front did not show advanced 
N grade or tumor stage (Table 1). In contrast, among all of the cases we studied, GC 
cases in which more than 50% of tumor cells were stained showed more advanced T 
grade (P = 0.0158, Fisher's exact test), N grade (P = 0.0035, Fisher's exact test) and 
tumor stage (P = 0.0466, Fisher's exact test) than those in which less than 50% of tumor 
cells were stained (Table 1). Therefore, when more than 50% of tumor cells were 
stained, the immunostaining was considered positive for h-prune. 
Association between h-prune and nm23-H1 expression. Because it has been 
suggested that overexpression of h-prune in breast cancer inhibits the antimetastasis 
function of nm23-H1 during metastasis,( 9,13) we also carried out immunohistochemical 
analysis of nm23-H1 in the same 143 GC cases. Consistent with previous reports,( 19) 
strong cytoplasmic staining of nm23-H1 was observed in tumor cells. In corresponding 
non-neoplastic mucosa, weak staining of nm23-H1 was observed. In the present study, 
to compare the h-prune staining pattern with the nm23-H1 staining pattern, the same 
cut-off point for nm23-H1 and h-prune immunostaining was set. When more than 50% 
of tumor cells were stained, the immunostaining was considered positive for nm23-H1. 
In total, 124 (87%) of 143 GC cases were positive for nm23-H1. The h-prune staining 
pattern was then compared with the nm23-H1 staining pattern. Of 43 h-prune-positive 
GC cases, 42 (98%) were positive for nm23-H1, and in these 42 GC cases there was a 
tendency for h-prune and nm23-H1 to be expressed in the same tumor cells (Fig. 3a,b). 
All 18 GC cases that were negative for both h-prune and nm23-H1 were signet ring cell 
carcinoma. In contrast, the majority (82 of 143 GC cases, 57%) of cases were positive 
for nm23-H1 but not h-prune (Fig. 3c,d). The frequency of nm23-H1 expression in 
h-prune-positive GC cases (42 of 43 cases, 98%) was significantly higher than that in 
h-prune-negative GC cases (82 of 100 cases, 82%, P = 0.0134, Fisher's exact test) 
(Table 2). 
We next analyzed the relationship between nm23-H1 expression and clinicopathological 
characteristics. Expression of nm23-H1 was not correlated with age, sex, T grade, N 
grade or tumor stage (Table 3). As reported previously,( 19) expression of nm23-H1 was 
observed more frequently in intestinal-type GC (79 of 85 cases, 93%) than in 
diffuse-type GC (45 of 58 cases, 78%, P = 0.0113, Fisher's exact test) (Table 3). It has 
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been reported that in the majority of nm23-H1-positive tumors, more than 75% of the 
tumor cells contained a homogeneous cytoplasmic pattern for nm23-H1.( 19) GC cases 
containing more than 75% of nm23-H1-positive tumor cells were found in 113 of 143 
GC cases. GC cases containing more than 75% of nm23-H1-positive tumor cells did not 
show advanced T grade, N grade or tumor stage (data not shown). Among the 
nm23-H1-positive GC cases, h-prune-positive GC cases showed advanced T grade 
(P = 0.0341, Fisher's exact test), N grade (P = 0.0083, Fisher's exact test) and tumor 
stage (P = 0.0371, Fisher's exact test) more frequently than h-prune-negative GC cases 
(Fig. 4a–c). In contrast, among h-prune-negative GC cases there was no statistically 
significant correlation between nm23-H1 positivity and T grade, N grade or tumor stage 
(Fig. 4a–c). 
We also examined the relationship between survival and expression of h-prune and 
nm23-H1 in GC (n = 84). On univariate analysis, T grade (P < 0.0001, log-rank test), N 
grade (P = 0.0474, log-rank test), tumor stage (P = 0.0001, log-rank test) and h-prune 
expression (P < 0.0001, log-rank test) (Fig. 4d) were significant prognostic factors of 
survival in patients with GC, whereas age, sex, histological type and nm23-H1 
expression (Fig. 4e) were not correlated with survival. Next, Cox proportional hazards 
multivariate model was used to examine the association of clinicopathological factors 
and the expression of h-prune with survival. Multivariate analysis indicated that T grade, 
N grade, tumor stage and h-prune expression were independent predictors of survival in 
patients with GC (Table 4). 
 
 
Discussion 
  
Metastasis fundamentally involves the movement of cells from one site to another. The 
molecular mechanisms that underlie cell migration involve dynamic cytoskeletal 
changes, cell–matrix interactions, localized proteolysis, actin–myosin contractions and 
focal contact disassembly.( 25) We reported previously that h-prune is localized to focal 
adhesions and that knockdown of h-prune inhibits cell motility. Suppression of tyrosine 
phosphorylation of FAK and activation of Rac are involved in inhibition of cell 
motility.( 8) In the present study, overexpression of PRUNE mRNA was observed in 
32% of cases by quantitative RT-PCR analysis, and cytoplasmic staining of h-prune 
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protein was observed in 30% of cases by immunohistochemistry in GC tissue samples. 
Expression of h-prune was correlated with T grade, N grade and tumor stage. In 
addition, patients with h-prune-positive GC had a significantly worse survival rate than 
patients with h-prune-negative GC. Taken together, these results suggest that extensive 
expression of h-prune contributes to the malignant behavior of GC, possibly by 
promoting cancer cell motility. H-prune may be a good marker of poor survival of GC. 
It is generally accepted that cancer progresses as a disease of genetically heterogeneous 
cell populations. In the present study, there were several cases in which 
h-prune-positive tumor cells were restricted to the invasive front. Among GC cases in 
which less than 50% of tumor cells were stained, GC cases in which h-prune-positive 
tumor cells were restricted to the invasive front showed more advanced T grade than 
those in which h-prune-positive tumor cells were not restricted to the invasive front; 
however, these GC cases comprised only 10% of 143 GC cases, and did not show 
advanced N grade or tumor stage, suggesting that expression of h-prune may represent 
tumor invasiveness, especially local invasiveness. Observation of the invasive front is 
important in the analysis of tumor cells, because it reflects the invasive potential of 
tumor cells. It has been reported that expression of matrilysin in the invasive front is a 
promising biomarker predicting nodal metastasis of colorectal cancers.( 26) 
Overexpression of heparanase at the invasive front has been reported in GC, and high 
expression of heparanase is a strong predictor of poor survival.( 27) These results indicate 
that the proteolytic degradation of extracellular matrix by these molecules is one of the 
most important mechanisms in tumor progression, and the proteolytic degradation 
occurs at the invasive front. Because h-prune promotes cell motility, expression of 
h-prune at the invasive front may partly contribute to the malignant behavior of GC, 
such as local invasiveness. 
The mechanism of regulation of h-prune expression is still unknown. In the present 
study, overexpression of PRUNE mRNA was observed in 32% by quantitative RT-PCR 
analysis, and h-prune-positive GC cases were found in 30% by immunohistochemistry. 
Because GC samples analyzed by quantitative RT-PCR were different from those 
analyzed by immunohistochemistry, we could not compare PRUNE mRNA levels with 
h-prune protein levels. However, these findings suggest that overexpression of PRUNE 
occurs at the transcriptional or mRNA level in GC. PRUNE amplification and 
overexpression have been reported in certain sarcomas and breast cancers.( 13) PRUNE is 
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located on chromosome 1q21.3, and gains of 1q21.1-21.2 and 1q21.3 have been 
reported in GC.( 28) Amplification of the PRUNE gene may be involved in 
overexpression of h-prune in GC cases. The main cause of peptic ulceration is 
Helicobacter pylori, and H. pylori is the strongest risk factor for the development of 
distal GC.( 29,30) Because stimulation of matrilysin by H. pylori has been reported,( 31) 
induction of h-prune by H. pylori should be examined in the near future. 
In the present study, immunohistochemical analysis of GC tissues revealed that almost 
all h-prune-positive GC cases (98%) also expressed nm23-H1. Expression of nm23-H1 
was found in both early- and late-stage GC, whereas expression of h-prune was detected 
mainly in late-stage tumors. In nm23-H1-positive GC cases, h-prune-positive GC cells 
may develop in accordance with tumor progression. In GC cases positive for both 
h-prune and nm23-H1, intratumoral distribution of h-prune-positive tumor cells and 
nm23-H1-positive tumor cells was similar, and many of these GC cases showed 
advanced T grade, N grade and tumor stage. Because the PDE activity of h-prune, 
which is involved in cellular motility, is enhanced by the interaction with nm23-H1,( 9) 
expression of both proteins may confer cellular motility to GC cells. Among 
h-prune-negative GC cases, there were no clear differences between nm23-H1 positivity 
and clinical characteristics, suggesting that expression of only nm23-H1 does not 
influence progression of GC. Although there was no impact of nm23-H1 expression on 
patient survival in the present study, it has been reported that high nm23-H1 expression 
correlates with tumor progression and poor prognosis.( 9) Expression of nm23-H1 may 
enhance the PDE activity of h-prune but may not have antimetastatic activity. All 18 
GC cases negative for both h-prune and nm23-H1 were signet ring cell carcinoma. 
Several reports have indicated that the prognosis of patients with signet ring cell 
carcinoma is relatively favorable in the early stages and poor in advanced stages 
compared with other histological types of GC.( 32) In fact, of 18 signet ring cell 
carcinoma cases, 12 cases showed stage I and the prognosis of patients with these GC 
was favorable. 
Epigenetic changes, such as DNA methylation of CpG islands, are detected commonly 
in human cancers. Hypermethylation of CpG islands is associated with silencing of 
many genes, especially defective tumor-related genes, and has been proposed as an 
alternative way to inactivate tumor-related genes in human cancers.( 33) GC show the 
CpG island methylator phenotype (CIMP).( 34,35) CIMP-positive GC also tend to show 
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DNA methylation of the p16INK4a,( 34) hMLH1( 6) and RIZ( 6) genes, suggesting that CIMP 
is an important pathway involved in stomach carcinogenesis. Because DNA methylation 
inhibitors such as 5-aza-2'-deoxycytidine have been shown to increase nm23-H1 
expression in breast cancer cells,( 36) h-prune or nm23-H1 expression may be associated 
with CIMP. 
Is h-prune a good therapeutic target for GC? Previous data indicated that dipyridamole, 
an antiplatelet aggregation drug, inhibits h-prune PDE activity and cellular motility in a 
breast cancer cell line.( 9) In the SW480 CRC cell line, knockdown of h-prune decreased 
cell motility.( 8) These results suggest that inhibition of h-prune may be useful for the 
prevention or treatment of metastasis. However, because h-prune is expressed 
ubiquitously in normal human adult tissues,( 11) inhibitors of h-prune, such as 
dipyridamole, may have severe adverse effects. However, it is known that components 
of the blood-clotting pathway contribute to metastasis by trapping tumor cells in 
capillaries or by facilitating adhesion of tumor cells to capillary walls. Anti-platelet 
aggregation drugs may interfere with this step in the metastatic process. In fact, several 
studies have indicated that the formation of metastatic tumors could be inhibited by 
antiplatelet aggregation drugs (reviewed by Hejna et al. (37)). In GC, combined 
chemotherapy with dipyridamole with adriamycin and 5-fluorouracil appears to be safe 
and may be useful clinically for treatment of GC.( 38) Taken together with our present 
results, h-prune inhibitors, such as dipyridamole, may be effective for the prevention or 
treatment of h-prune-positive GC without severe adverse effects. The PDE superfamily 
is large and complex, containing 11 highly related and structurally related gene families 
and over 60 distinct isoforms. Each of the PDE families contains one to four genes, and 
many genes generate multiple isoforms.( 39) Development of specific h-prune inhibitors 
is important because dipyridamole also inhibits the activities of PDE5, PDE6, PDE7, 
PDE8, PDE10 and PDE11.( 39) 
In conclusion, we found that h-prune is overexpressed in GC and that this 
overexpression correlates with tumor progression and poor survival in patients with GC. 
Although the significance of overexpression of nm23-H1 is still unclear, nm23-H1 may 
contribute to tumor cell motility by upregulating the function of h-prune. Although the 
precise mechanism by which h-prune regulates cellular motility remains unclear, the 
efficacy of a combination chemotherapy with 5-fluorouracil, cisplatin and 
dipyridamole( 40) should be investigated in h-prune-positive GC. 
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Table 1 
Association of h-prune expression with clinicopathologic features of gastric cancer 
  h-prune expression (%)   
  Positive Invasion 
front positive
Negative P 
value† 
P 
value‡ 
Age       
 > 65 20 (25%) 6 (7%) 55 0.1504 0.1410
 ≤ 65 23 (37%) 8 (13%) 31   
Sex       
 Male 25 (27%) 10 (11%) 57 0.7703 0.3442
 Female 18 (35%) 4 (8%) 29   
T grade§       
 T1 11 (19%) 2 (3%) 46 0.0083 0.0158
 T2/3/4 32 (38%) 12 (14%) 40   
N grade§       
 N0 16 (20%) 6 (8%) 58 0.1305 0.0035
 N1/2/3 27 (43%) 8 (13%) 28   
Stage§       
 Stage I/II 25 (25%) 8 (8%) 68 0.0944 0.0466
 Stage III/IV 18 (43%) 6 (14%) 18   
Histologic type¶      
 Intestinal 22 (26%) 9 (11%) 54 1.0000 0.1988
 Diffuse 21 (36%) 5 (9%) 32   
†Invasion front positive vs. Negative. Statistical significance was determined with Fisher's 
exact test. 
‡Positive vs. Invasion front positive plus Negative. Statistical significance was determined 
with Fisher's exact test. 
§Stage was classified according to the criteria of the International Union Against Cancer TNM 
classification of malignant tumors, 6th edition, 2002. 
¶Histology was classified according to the criteria of Lauren. 
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Table 2 
Distribution of h-prune and nm23-H1 expression in gastric cancer 
    nm23-H1 expression  
  Positive Negative P value† 
h-prune expression    
 Positive 42 (98%) 1 0.0134 
 Negative 82 (82%) 18  
†Statistical significance was determined with Fisher's exact test. 
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Table 3 
Association of nm23-H1 expression with clinicopathologic features of gastric cancer 
  nm23-H1 expression (%)  
  Positive Negative P value† 
Age     
 > 65 70 (86%) 11 1.0000 
 ≤ 65 54 (87%) 8  
Sex     
 Male 80 (87%) 12 1.0000 
 Female 44 (86%) 7  
T grade‡     
 T1 49 (83%) 10 .3220 
 T2/3/4 75 (89%) 9  
N grade‡     
 N0 68 (85%) 12 .6219 
 N1/2/3 56 (89%) 7  
Stage‡     
 Stage I/II 88 (87%) 13 .7926 
 Stage III/IV 36 (86%) 6  
Histologic type§     
 Intestinal 79 (93%) 6 .0113 
 Diffuse 45 (78%) 13  
†Statistical significance was determined with Fisher's exact test. 
‡Stage was classified according to the criteria of the International Union Against Cancer TNM 
classification of malignant tumors, 6th edition, 2002. 
§Histology was classified according to the criteria of Lauren. 
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Table 4 
Multivariate analysis of factors influencing survival 
Factor  Hazard ratio (95% CI) χ2 P value 
T grade†      
 T1 1 (Reference) 7.42 0.0064 
 T2/3/4 18.99 (2.28-157.86)   
N grade†     
 N0 1 (Reference) 5.57 0.0182 
 N1/2/3 8.24 (1.43-47.46)   
Stage†     
 Stage I/II 1 (Reference) 5.71 0.0168 
 Stage III/IV 6.42 (1.39-29.43)   
h-prune expression    
 Negative 1 (Reference) 8.18 0.0043 
 Positive 4.87 (1.63-14.48)   
†Stage was classified according to the criteria of the International Union Against Cancer TNM 
classification of malignant tumors, 6th edition, 2002. 
 
